Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 21;110(Supplement_1):S67-S73.
doi: 10.1210/clinem/dgae710.

Barriers to the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

Affiliations
Review

Barriers to the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

Kelsey B Eitel et al. J Clin Endocrinol Metab. .

Abstract

Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a rare genetic condition that requires lifelong management from birth. Individuals with CAH and their families often face structural barriers to obtaining comprehensive care and treatment, including limited access to appropriate newborn screening, comprehensive care centers, and medications. Social and cultural barriers to care may include stigmatization, discrimination, and adverse medical experiences. At the individual and family level, comprehensive care may be affected by education, finances, health-care coverage, geographic location, and lack of social supports. These barriers are often further magnified for individuals living in underresourced countries. Inadequate access to comprehensive care and medications increases the risk of life-threatening adrenal crisis and disease-related comorbidities. This review article examines the current structural, sociocultural, and individual barriers that individuals with CAH and their families may face when managing their condition throughout their lifetime.

Keywords: access; barrier; congenital adrenal hyperplasia; education; screening; stigma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Barriers in the diagnosis and management of congenital adrenal hyperplasia.
Figure 2.
Figure 2.
Multidisciplinary care team for congenital adrenal hyperplasia management.

Similar articles

Cited by

References

    1. Merke DP, Auchus RJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 2020;383(13):1248‐1261. - PubMed
    1. Auer MK, Nordenstrom A, Lajic S, Reisch N. Congenital adrenal hyperplasia. Lancet. 2023;401(10372):227‐244. - PubMed
    1. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043‐4088. - PMC - PubMed
    1. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia: current insights in pathophysiology, diagnostics, and management. Endocr Rev. 2022;43(1):91‐159. - PMC - PubMed
    1. Mallappa A, Merke DP. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev Endocrinol. 2022;18(6):337‐352. - PMC - PubMed

Supplementary concepts

LinkOut - more resources